Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

Marcovina, 1998, Lipoprotein(a) as a risk factor for coronary artery disease., Am J Cardiol, 82, 57U, 10.1016/S0002-9149(98)00954-0

Erqou, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality., JAMA, 302, 412, 10.1001/jama.2009.1063

Kamstrup, 2009, Genetically elevated lipoprotein(a) and increased risk of myocardial infarction., JAMA, 301, 2331, 10.1001/jama.2009.801

Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease., N Engl J Med, 361, 2518, 10.1056/NEJMoa0902604

Nordestgaard, 2016, Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology., J Lipid Res, 57, 1953, 10.1194/jlr.R071233

Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy., N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579

Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients., N Engl J Med, 371, 203, 10.1056/NEJMoa1300955

Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events., N Engl J Med, 357, 2109, 10.1056/NEJMoa0706628

Lincoff, 2017, Evacetrapib and cardiovascular outcomes in high-risk vascular disease., N Engl J Med, 376, 1933, 10.1056/NEJMoa1609581

Bowman, 2017, Effects of anacetrapib in patients with atherosclerotic vascular disease., N Engl J Med, 377, 1217, 10.1056/NEJMoa1706444

Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease., N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664

Viney, 2016, Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials., Lancet, 388, 2239, 10.1016/S0140-6736(16)31009-1

Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status., Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386

Bennet, 2008, Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data., Arch Intern Med, 168, 598, 10.1001/archinte.168.6.598

Emdin, 2016, Phenotypic characterization of genetically lowered human lipoprotein(a) levels., J Am Coll Cardiol, 68, 2761, 10.1016/j.jacc.2016.10.033

Kamstrup, 2008, Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study., Circulation, 117, 176, 10.1161/CIRCULATIONAHA.107.715698

Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials., Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5

Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials., Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5

Silverman, 2016, Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis., JAMA, 316, 1289, 10.1001/jama.2016.13985

Teslovich, 2010, Biological, clinical and population relevance of 95 loci for blood lipids., Nature, 466, 707, 10.1038/nature09270

Burgess, 2016, Combining information on multiple instrumental variables in mendelian randomization: comparison of allele score and summarized data methods., Stat Med, 35, 1880, 10.1002/sim.v35.11

Staley, 2017, Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to mendelian randomization., Genet Epidemiol, 41, 341, 10.1002/gepi.2017.41.issue-4

Nikpay, 2015, A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease., Nat Genet, 47, 1121, 10.1038/ng.3396

Boerwinkle, 1992, Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations., J Clin Invest, 90, 52, 10.1172/JCI115855

Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease., JAMA, 302, 1993, 10.1001/jama.2009.1619

Ference, 2015, Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial mendelian randomization study., J Am Coll Cardiol, 65, 1552, 10.1016/j.jacc.2015.02.020

Ference, 2016, Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes., N Engl J Med, 375, 2144, 10.1056/NEJMoa1604304

Pedersen, 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)., Lancet, 344, 1383

Parish, 2018, Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study., Circ Genom Precis Med, 11, e001696, 10.1161/CIRCGEN.117.001696

Ference, 2017, Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk., JAMA, 318, 947, 10.1001/jama.2017.11467

Ference, 2018, How to use mendelian randomization to anticipate the results of randomized trials., Eur Heart J, 39, 360, 10.1093/eurheartj/ehx462

Varvel, 2016, Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States., Arterioscler Thromb Vasc Biol, 36, 2239, 10.1161/ATVBAHA.116.308011

Langsted, 2016, High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study., Lancet Diabetes Endocrinol, 4, 577, 10.1016/S2213-8587(16)30042-0

Langsted, 2017, High lipoprotein(a) and low risk of major bleeding in brain and airways in the general population: a mendelian randomization study., Clin Chem, 63, 1714, 10.1373/clinchem.2017.276931